| Literature DB >> 35005367 |
Heather D Hadjistavropoulos1, Luke H Schneider1, Thomas Hadjistavropoulos1, Nickolai Titov2, Blake F Dear3.
Abstract
BACKGROUND: Access to face-to-face cognitive behavioral pain management programs is very limited. Internet-delivered cognitive behavioral pain management has potential to improve client access to care but is not readily available in Canada. AIMS: The present study explored the effectiveness, acceptability, and feasibility of a previously validated Internet-delivered cognitive behavioral pain management course, the Pain Course, when offered in a publicly funded provincial Online Therapy Clinic. The five-lesson course was delivered over 8 weeks and was accompanied by brief weekly contact from a coach via weekly telephone calls and secure online messages.Entities:
Keywords: Internet-delivered; anxiety; chronic pain; cognitive behavioral therapy; depression
Year: 2018 PMID: 35005367 PMCID: PMC8730648 DOI: 10.1080/24740527.2018.1442675
Source DB: PubMed Journal: Can J Pain ISSN: 2474-0527
Patient characteristics and program engagement.
| % | ||
|---|---|---|
| Age | ||
| Mean (SD) | 44.07 (14.09) | — |
| Range | 21–70 | — |
| Gender | ||
| Male | 16 | 29 |
| Female | 39 | 71 |
| Marital status | ||
| Single/never married | 12 | 22 |
| Married/common law | 34 | 62 |
| Separated/divorced/widowed | 7 | 13 |
| Undisclosed | 2 | 3 |
| Education | ||
| Less than high school | 1 | 2 |
| High school diploma | 11 | 20 |
| Post high school certificate/diploma | 13 | 24 |
| University education | 30 | 54 |
| Employment status | ||
| Employed part-time/full-time | 21 | 38 |
| Unemployed | 5 | 9 |
| Homemaker | 2 | 4 |
| Student | 3 | 5 |
| Retired | 6 | 11 |
| Short-term disability | 8 | 15 |
| Long-term disability | 10 | 18 |
| Ethnicity | ||
| Caucasian | 49 | 89 |
| Indigenous | 2 | 4 |
| Other | 3 | 5 |
| Undisclosed | 1 | 2 |
| Location | ||
| Large city (over 200,000) | 25 | 45 |
| Small city | 14 | 26 |
| Small rural location | 16 | 29 |
| Duration of pain symptoms (years) | ||
| Mean (SD) | 6.00 (7.53) | — |
| Range | 0.25–42.00 | — |
| Pain location | ||
| Upper back/middle back/lower back | 43 | 78 |
| Hip/pelvis/leg/foot | 36 | 65 |
| Shoulder/arm/hand | 25 | 45 |
| Head/face | 19 | 35 |
| Other | 13 | 24 |
| Average number of pain sites (SD) | 4.51 (3.06) | — |
| Prescription medication | ||
| Pain | 44 | 88 |
| Mental health | 29 | 53 |
| Prescription medications reporteda | ||
| Strong opioid analgesics | 18 | 33 |
| Weak opioid analgesics | 11 | 20 |
| Anticonvulsants | 16 | 29 |
| Nonsteroidal anti-inflammatories | 12 | 22 |
| Muscle relaxants | 4 | 7 |
| Benzodiazepines | 5 | 9 |
| Anxiolytics and antidepressants | 37 | 67 |
| Other pain or mental health medications | 13 | 24 |
| Mean number of prescription medications reported (SD) | 2.11 (1.55) | — |
| Mental health characteristics | ||
| Infrequent use of some form of mental health treatment | 25 | 45 |
| Pretreatment GAD-7 ≥ 10 | 23 | 42 |
| Pretreatment PHQ-9 ≥ 10 | 42 | 76 |
| Program engagement | ||
| Completion of four lessons | 48 | 87 |
| Completion of five lessons | 42 | 76 |
| Completion of posttreatment questionnaires | 46 | 84 |
| Completion of 3-month follow-up questionnaires | 34 | 62 |
| Mean number of log-ins (SD) | 22.18 (14.97) | — |
| Mean days between first and last log-in (SD) | 86.51 (49.88) | — |
| Mean number of phone calls with therapist (SD) | 5.40 (2.05) | — |
| Mean written messages sent to therapist (SD) | 2.36 (2.76) | — |
| Mean written messages received from therapist (SD) | 4.60 (2.05) | — |
aOnly prescription medications for pain, a pain-related condition, anxiety, or depression are reported. Strong opioids: buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone; weak opioids: codeine, tramadol, tapentadol; anxiolytics, and antidepressants: beta-blockers, selective serotonin reuptake inhibitors, norepinephrine and serotonin–norepinephrine reuptake inhibitors, tricyclics, and tetracyclics; other psychotropic or pain medications: corticosteroids, antispasmodics, serotonin agonists, dopamine agonists, antipsychotics, and psychostimulants.
GAD-7 = Generalized Anxiety Disorder 7-Item; PHQ-9 = Patient Health Questionnaire 9-Item.
Figure 1.Participant flowchart.
Means, standard deviations, and effect sizes for the primary and secondary outcome measures.a
| Estimated marginal mean values | Percentage change from baselineb | Cohen’s | |||||
|---|---|---|---|---|---|---|---|
| Pretreatment | Posttreatment | 3-Month follow up | Posttreatment | 3-Month follow up | Posttreatment | 3-Month follow up | |
| Primary outcomes | |||||||
| GAD-7 | 9.33 (5.40) | 6.36 (6.00) | 6.49 (6.62) | 32 (12 to 47) | 30 (9 to 47) | 0.52 (0.14 to 0.90) | 0.47 (0.09 to 0.85) |
| PHQ-9 | 13.07 (5.48) | 8.33 (5.67) | 9.10 (6.83) | 36 (24 to 47) | 30 (15 to 43) | 0.85 (0.46 to 1.24) | 0.64 (0.26 to 1.02) |
| RMDQ | 14.44 (4.93) | 11.84 (6.48) | 11.19 (6.41) | 18 (6 to 30) | 22 (11 to 34) | 0.45 (0.07 to 0.83) | 0.57 (0.19 to 0.95) |
| Secondary outcomes | |||||||
| BPI-Severity | 5.15 (1.74) | 4.94 (1.95) | 4.70 (1.75) | 4 (−6 to 14) | 9 (0 to 18) | 0.11 (−0.26 to 0.49) | 0.26 (−0.12 to 0.63) |
| CPAQ-8 | 18.91 (8.38) | 25.16 (9.35) | 26.42 (9.12) | 25 (16 to 34) | 28 (20 to 37) | 0.70 (0.32 to 1.09) | 0.86 (0.47 to 1.25) |
| PSEQ | 24.18 (11.73) | 34.20 (12.51) | 40.48 (26.02) | 29 (20 to 38) | 40 (33 to 48) | 0.83 (0.44 to 1.22) | 0.81 (0.42 to 1.20) |
| TSK | 41.15 (7.08) | 37.20 (7.70) | 39.21 (10.85) | 10 (4 to 14) | 5 (−3 to 11) | 0.53 (0.15 to 0.91) | 0.21 (−0.16 to 0.59) |
aSDs and confidence intervals are shown in parentheses for means, percentage change, and effect sizes, respectively.
bThe percentage change from baseline statistics are estimates of relative change derived from the GEE models conducted separately for each outcome.
GAD-7 = Generalized Anxiety Disorder 7-Item; PHQ-9 = Patient Health Questionnaire 9-Item; RMDQ = Roland Morris Disability Measure; BPI = Brief Pain Inventory; CPAQ-8 = Chronic Pain Acceptance Questionnaire 8-Item; PSEQ = Pain Self-Efficacy Questionnaire; TSK = TAMPA Scale of Kinesiophobia.